Tesamorelin vs CJC-1295: two GHRH analogues

A comparison that is actually like-for-like

Most compound comparisons in this market pair two molecules that share a shelf and nothing else. This one is different. Tesamorelin and CJC-1295 are both analogues of growth-hormone-releasing hormone, both engage the GHRH receptor, and both exist because native GHRH is degraded too quickly to study conveniently. They are two engineering solutions to the same problem.

That shared starting point is what makes the differences legible. Where they diverge — chain length, the chemistry used to resist degradation, and how thoroughly each has been characterised — is where the useful information sits.

The degradation problem both solve

Native GHRH is cleaved rapidly by dipeptidyl peptidase-4, an enzyme that removes residues from the N-terminal end of susceptible peptides. Any GHRH analogue intended for study has to address that cleavage or it disappears before anything can be measured.

Tesamorelin's approach is chemical protection at the vulnerable end: a trans-3-hexenoyl group attached to the N-terminus of the full 44-residue sequence, physically obstructing the enzyme's access. CJC-1295's approach is sequence substitution: amino acid replacements at the positions most vulnerable to cleavage within a shortened 29-residue analogue of the hormone's active region.

Both approaches work by making the molecule a poorer substrate for the same enzyme. Neither changes which receptor the peptide engages, which is why the two remain in one class despite looking quite different on paper.

Side-by-side identity data

The molar row deserves attention because it runs opposite to intuition. Tesamorelin's higher molecular weight means an identically labelled 5 mg vial contains about a third fewer molecules than the CJC-1295 vial beside it. Mass on the label is not the quantity that matters chemically, and the gap here is large enough to change conclusions.

Why one has a far deeper literature

Tesamorelin's molecule went through the full pharmaceutical development path, including controlled clinical trials, and reached FDA approval as a prescription product. That produced something almost nothing else in this catalog has: a documented pharmacokinetic profile, a characterised adverse-event set, and a manufacturing standard established under regulatory scrutiny.

CJC-1295 has no equivalent record. Its literature is preclinical and early-phase, and the picture is complicated by the two chemically distinct forms — with and without the albumin-binding DAC modification — that are frequently discussed as though they were one compound.

What each certificate has to show

• ◆Tesamorelin: mass near 5135.85 g/mol. A figure near 5030 suggests the unmodified GHRH(1-44) sequence without the hexenoyl group — a different molecule, and the modification is the entire point.
• ◆CJC-1295 (no DAC): mass near 3367.89 g/mol, with a substantially higher figure suggesting the DAC-modified form instead.
• ◆Both: at 44 and 29 residues these are long synthetic peptides, where deletion sequences — chains missing a single residue — are the characteristic impurity. They elute close to the main peak, so peak shape and resolution matter alongside the purity percentage.
• ◆Both: the certificate should name the issuing laboratory and the lot on your vial. For a compound with an approved counterpart, a vague certificate is a particularly poor trade.

Handling notes that follow from the chemistry

Both are long peptides and both adsorb to container surfaces at low concentrations, Tesamorelin somewhat more so by virtue of length. Both are lyophilised powders that take up moisture from the air, so a vial opened repeatedly at room temperature accumulates water it will not lose again.

Neither compound's stability profile has an exotic single point of failure, unlike the methionine oxidation route in TB-500 or the copper dissociation route in GHK-Cu. What they have instead is the ordinary vulnerability of long chains: more peptide bonds means more places for hydrolysis to occur, which is why time in solution is the variable worth controlling.